Department of Veterinary Integrative Biosciences, Texas A&M University, College Station, Texas, USA.
Clin Pharmacol Ther. 2019 May;105(5):1175-1186. doi: 10.1002/cpt.1259. Epub 2018 Dec 2.
"Thorough QT/corrected QT (QTc)" (TQT) studies are cornerstones of clinical cardiovascular safety assessment. However, TQT studies are resource intensive, and preclinical models predictive of the threshold of regulatory concern are lacking. We hypothesized that an in vitro model using induced pluripotent stem cell (iPSC)-derived cardiomyocytes from a diverse sample of human subjects can serve as a "TQT study in a dish." For 10 positive and 3 negative control drugs, in vitro concentration-QTc, computed using a population Bayesian model, accurately predicted known in vivo concentration-QTc. Moreover, predictions of the percent confidence that the regulatory threshold of 10 ms QTc prolongation would be breached were also consistent with in vivo evidence. This "TQT study in a dish," consisting of a population-based iPSC-derived cardiomyocyte model and Bayesian concentration-QTc modeling, has several advantages over existing in vitro platforms, including higher throughput, lower cost, and the ability to accurately predict the in vivo concentration range below the threshold of regulatory concern.
“全面 QT/校正 QT(QTc)”(TQT)研究是临床心血管安全性评估的基石。然而,TQT 研究需要大量资源,并且缺乏能够预测监管关注阈值的临床前模型。我们假设,使用来自不同人类受试者的诱导多能干细胞(iPSC)衍生的心肌细胞的体外模型可以作为“TQT 研究在培养皿中”。对于 10 种阳性和 3 种阴性对照药物,使用群体贝叶斯模型计算的体外浓度-QTc 准确预测了已知的体内浓度-QTc。此外,预测监管阈值 10ms QTc 延长的置信度百分比与体内证据也一致。这种“TQT 研究在培养皿中”,由基于群体的 iPSC 衍生的心肌细胞模型和贝叶斯浓度-QTc 建模组成,与现有的体外平台相比具有几个优势,包括更高的通量、更低的成本,并且能够准确预测监管关注阈值以下的体内浓度范围。